千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务

证券之星05-27

证券之星消息，千红制药(002550)05月26日在投资者关系平台上答复投资者关心的问题。

投资者提问：请问:公司收到交易所关于申请发行可转换债券问询函是属于重大事项？为什么没有发布收到该问询函的公告？

千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据相关监管要求进行了科学合理的工作推进安排并及时公告。感谢您的关注。

以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2638735555?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-27 11:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638735555","market":"sh","top_or_hot":-1,"title":"千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/002550\">千红制药</a>(002550)05月26日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：请问:公司收到交易所关于申请发行可转换债券问询函是属于重大事项？为什么没有发布收到该问询函的公告？</p><p>千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据相关监管要求进行了科学合理的工作推进安排并及时公告。感谢您的关注。</p><p>以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-27 11:36 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026052700019949.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，千红制药(002550)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问:公司收到交易所关于申请发行可转换债券问询函是属于重大事项？为什么没有发布收到该问询函的公告？千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据相关监管要求进行了科学合理的工作推进安排并及时公告。感谢您的关注。以上内容为证券之星据公开信息...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026052700019949.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://stock.stockstar.com/RB2026052700019949.shtml","article_id":"2638735555","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638735555","pubTimestamp":1779853004,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，千红制药(002550)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问:公司收到交易所关于申请发行可转换债券问询函是属于重大事项？为什么没有发布收到该问询函的公告？千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据相关监管要求进行了科学合理的工作推进安排并及时公告。感谢您的关注。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0239":"医药制造","002550":"千红制药"},"translate_title":"Qianhong Pharmaceutical: The company fulfills its information disclosure obligations in strict accordance with the relevant regulations of the CSRC and the Exchange on the response to inquiry letters","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002550":1.5},"content_text":"证券之星消息，千红制药(002550)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问:公司收到交易所关于申请发行可转换债券问询函是属于重大事项？为什么没有发布收到该问询函的公告？千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据相关监管要求进行了科学合理的工作推进安排并及时公告。感谢您的关注。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638735555","isCrawlerRequest":true}